CICERODX, INC.

Medtech · Private

Blood/saliva/urine biomarker test for endometriosis detection using BCL6 and SIRT1 expression

Grants
$1.1M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
—
No published records under this name
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase II · SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$150,000
Federal grantDepartment of Health and Human Services · Phase II · SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$512,762
Federal grantDepartment of Health and Human Services · Phase II · SIRT1 and BCL6: Dual Biomarkers of Endometriosis and Endometrial Receptivity$463,322
Federal grant · SBIR/STTR

Peer position

Medtech · 4531 companies · ranked on federal contract value
Medtech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2212Cardiac Dynamics LLC——
2213BELAY DIAGNOSTICS, LLC——
2214VANISH THERAPEUTICS INC——
2215CICERODX, INC.——
2216Elk Valley Enterprises, Inc.——
2217MICROVASCULAR THERAPEUTICS LLC——
2218TRULY TECHNOLOGIES LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Regulatory activity · Medtech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.